The present technology relates generally to cryotherapeutic devices (e.g., cryotherapeutic catheters including balloons configured to expand within the vasculature of a patient). In particular, several embodiments are directed to shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods.
Cryotherapy can be a useful treatment modality in a wide range of catheter-based interventional procedures. For example, cryotherapeutic cooling can be used to modulate nerves or affect other tissue proximate anatomical vessels and other lumens or cavities in the body. This can reduce undesirable neural activity to achieve therapeutic benefits. Catheter-based neuromodulation utilizing cryotherapy can be used, for example, to modulate nerves and thereby reduce pain, local sympathetic activity, systemic sympathetic activity, associated pathologies, and other conditions. Cryotherapy can also be used for ablating tumors, treating stenosis, and other applications. In some cryotherapeutic procedures, it can be useful to deliver cryotherapy via a balloon that can be expanded within an anatomical vessel or lumen. Such balloons can be operatively connected to extracorporeal support components (e.g., refrigerant supplies). As the applicability of cryotherapy for surgical intervention continues to expand, there is a need for innovation in the associated devices, systems, and methods (e.g., with respect to efficacy, efficiency, and/or reliability). Such innovation has the potential to further expand the role of cryotherapy as a tool for improving the health of patients.
Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. Furthermore, components can be shown as transparent in certain views for clarity of illustration only and not to indicate that the illustrated component is necessarily transparent.
Specific details of several embodiments of the present technology are described herein with reference to
In cryotherapeutic procedures, it can be desirable to apply cooling with high selectivity. Reducing cooling of non-targeted structures and tissue can enhance cooling efficiency and reduce complications. Although both high-pressure refrigerants and low-temperature refrigerants are potentially useful for cryotherapy, high-pressure refrigerants can be particularly well suited for delivering intense, targeted cooling to specific locations within the body, particularly in relatively small-diameter catheters. In many cases, the cooling potential of high-pressure refrigerants can be maintained more readily during transport through the catheter than low-temperature refrigerants. For example, a suitable strong-walled conduit can be used to convey a high-pressure refrigerant from an extracorporeal source to a delivery location at a distal end of a catheter with relatively little loss of cooling potential because the cooling action occurs upon expansion of the refrigerant at the distal end of the catheter. In contrast, as a low-temperature refrigerant moves along a catheter, it can be difficult to prevent the low-temperature refrigerant from absorbing heat from surrounding structures and tissue. Thermal insulation can be used to control such heat transfer to some extent, but adequate thermal insulation can be excessively bulky for use in modern, small-diameter catheters.
While advantageous in many respects, the use of high-pressure refrigerants can place certain constraints on catheter construction. For example, tubes configured to carry refrigerant supplies typically are constructed of metal, hard polymers (e.g., polyimides), or other suitable materials, and have wall thicknesses that allow the tubes to have pressure ratings higher than the pressures of the refrigerants they are configured to transport. After a high-pressure refrigerant undergoes expansion and cooling, its pressure can decrease dramatically. Accordingly, the catheter components that contain the refrigerant after expansion are not limited to strong-walled tubes and similar high-strength structures with pressure ratings higher than the pressures of the refrigerant before expansion. Furthermore, some cryotherapeutic procedures use balloons because they can be relatively compact when not inflated, thereby allowing for delivery through narrow anatomical vessels and lumens, and they can expand to generally conform to the size and shape of the treatment location. Balloons also can have relatively thin walls well suited for cryotherapeutic heat transfer. Thin-walled cryotherapy balloons, however, typically have relatively low pressure ratings. For example, cryotherapeutic balloons typically have pressure ratings well below the supply pressures of suitable high-pressure refrigerants.
In some embodiments of the present technology, a high-pressure refrigerant can be transported along at least a portion of the length of a catheter and then expanded to a relatively low-temperature and low-pressure state via the Joule-Thomson effect alone or in combination with evaporative cooling. The catheter can be constructed such that the expansion can occur at or near a balloon. With a sufficient pressure drop, cooling from near ambient temperatures to cryogenic temperatures can be achieved. Suitable refrigerants for pressurization and expansion in cryotherapeutic devices include, for example, N2O, CO2, and hydrofluorocarbons (e.g., Freon® refrigerant, R-410A, etc.), among others. To maintain a pressure drop within a balloon, an exhaust passage can be provided from the balloon to the atmosphere or to a low-pressure containment vessel. Since expanded refrigerant has a lower density than high-pressure refrigerant, the exhaust passage can have a greater free-passage area than a corresponding supply lumen. During normal operation, evacuation of expanded refrigerant via the exhaust passage maintains the pressure in the balloon sufficiently below the high pressures associated with the refrigerant supply.
If the exhaust passage is blocked while the supply of high-pressure refrigerant to the balloon continues, the pressure in the balloon can build up until it equilibrates with the pressure of the supply lumen. Similarly, the pressure in the balloon can approach a lower, but still elevated, pressure if the exhaust passage becomes partially blocked. The exhaust passage can be partially or fully blocked, for example, due to an operator error (e.g., if an extracorporeal line carrying the exhaust passage becomes kinked or compressed or if a backpressure control valve is closed unexpectedly). In these and other such scenarios, it is possible that the pressure within the balloon can exceed the pressure rating of the balloon, which can be related to the pressure at which the balloon is likely to fail. Balloon failures can include, for example, bursting, leakage, excessive expansion (e.g., beyond the elastic tolerances of surrounding anatomical vessels or lumens), or combinations thereof. In some cases, the pressure rating of a balloon can correspond to a burst pressure of the balloon. It is undesirable for balloons to fail during a procedure for a number of reasons.
Cryotherapeutic devices, systems, and methods configured in accordance with embodiments of the present technology can include one or more features useful for reducing the likelihood of balloon failures (e.g., associated with excessive pressure build up within a balloon due to partial or complete blockage of an exhaust passage). For example, some embodiments can include one or more features configured to release pressure automatically when the pressure within the balloon is about to reach, reaches, or exceeds a predetermined threshold relative to the pressure rating of the balloon or another pressure level. These features can prevent or at least mitigate undesirable balloon failure.
The treatment catheter 104 can include an elongated shaft 108 and a balloon 110 at a distal portion 112 of the shaft 108. The shaft 108 can be configured to locate the distal portion 112 within a vessel or lumen of a human patient. The treatment catheter 104 can further include a guide lumen 114 and a supply lumen 116 extending along at least a portion of the shaft 108, and the supply lumen 116 can have an orifice 118 within the balloon 110. The balloon 110 can extend from a stepped-down segment 120 of the distal portion 112 to an outer surface of the guide lumen 114. The supply lumen 116 can be configured to supply high-pressure refrigerant to the balloon 110 via the orifice 118. The high-pressure refrigerant can change phase from a liquid to a gas within the balloon 110, which can expand and cool the balloon 110. The treatment catheter 104 can also have an exhaust passage 122 extending proximally from the balloon 110 along at least a portion of the shaft 108 (e.g., around the guide lumen 114 and the supply lumen 116) to the atmosphere or an extracorporeal containment vessel (not shown). During operation, refrigerant flows to the balloon 110 through the supply lumen 116 and out of the balloon 110 via the exhaust passage 122. The exhaust passage 122 can have a greater free-passage area than the supply lumen 116 to accommodate the lower density of expanded refrigerant relative to the high-pressure refrigerant within the supply lumen 116.
As shown in
The shaft 108 can further include a pressure-relief portion 124 located proximally relative to the distal portion 112. In some embodiments, the distal portion 112 can extend along an entire length of the treatment catheter 104 between the pressure-relief portion 124 and the balloon 110. In other embodiments, the shaft 108 can include an intermediate portion (not shown) between the pressure-relief portion 124 and the distal portion 112. The pressure-relief portion 124 can be configured to release refrigerant from the exhaust passage 122 (e.g., to a space in the guide passage 125 between the treatment catheter 104 and the guide catheter 102) when a pressure of refrigerant in at least a portion of the exhaust passage 122 (e.g., a portion at or near the pressure-relief portion 124), the balloon 110, or both exceeds a threshold pressure. The threshold pressure, for example, can be less than a pressure rating of the balloon 110 (e.g., a pressure rating corresponding to a burst pressure of the balloon 110).
As shown in
The lap joint 126 can provide a particularly strong connection between the first and second segments 108a-b, but other connections can also be used. For example,
With reference to
The wall strength of the pressure-relief portion 124, 308 or the second segment 108b, 304b can be selected to cause the pressure-relief portion 124, 308 or the second segment 108b, 304b to rupture at about the threshold pressure. Accordingly, the pressure-relief portion 124, 308 or the second segment 108b, 304b can be sacrificial and/or otherwise configured to fail before the balloon 110 fails during a malfunction in which the pressure in the balloon 110 increases unexpectedly. Failure of the pressure-relief portion 124, 308 or the second segment 108b, 304b can allow refrigerant to quickly flow into the space in the guide passage 125 between the shaft 108 and the guide catheter 102. At least a portion of the refrigerant in the space can then move proximally to a proximal opening (not shown) of the guide catheter 102. In some embodiments, the pressure-relief portion 124, 308 or the second segment 108b, 304b can be configured to rupture relatively rapidly. For example, the pressure-relief portion 124, 308 or the second segment 108b, 304b can include a relatively brittle material, such as a material having an elongation at break less than about 50% (e.g., less than about 30% or less than about 20%). In other embodiments, the pressure-relief portion 124, 308 or the second segment 108b, 304b can be configured to rupture more slowly.
In the cryotherapeutic systems 100, 300 shown in
With reference to
With reference again to
In some embodiments the diameter of the treatment catheter 502 and/or the diameter of the guide catheter 510 can be selected to size the space therebetween in the guide passage 125. For example, a difference between the outer diameter of the shaft 504 at and the inner diameter of the guide passage 125 can be greater than about 0.2 mm (e.g., greater than about 0.3 mm or greater than about 0.4 mm) along at least about 100 cm of the shaft 504 extending proximally from the pressure-relief portion 506. In some cases, however, it can be useful to reduce the size of the space in the guide passage 125 in favor of increasing the size of the shaft 504. For example, larger-diameter shafts can support greater cooling.
The pressure-relief portion 606 and portions of the shaft 604 proximal to the pressure-relief portion 606 can have a smaller diameter than the distal portion 112 such that there is more space between the proximal portion of the shaft 604 and the guide catheter 602. This can facilitate the proximal flow of refrigerant along the space within the guide passage 125 (e.g., from a release location proximate the rupture element 608 along a generally continuous path to a proximal opening of the guide catheter 603). The path, for example, can be greater than about 100 cm (e.g., greater than about 200 cm or greater than about 300 cm) in length and can extend proximally from the rupture element 608. In some embodiments, the pressure-relief portion 606 can be configured to deform from a first state (not shown) in which the pressure-relief portion 606 has a diameter similar to the diameter of the distal portion 112 to a second state (shown in
In some embodiments, the disclosed pressure-relief features can be redundant to other features intended to prevent balloon failures. For example, the cryotherapeutic systems shown in
The above detailed descriptions of embodiments of the present technology are for purposes of illustration only and are not intended to be exhaustive or to limit the present technology to the precise form(s) disclosed above. Various equivalent modifications are possible within the scope of the present technology, as those skilled in the relevant art will recognize. For example, while stages may be presented in a given order, alternative embodiments may perform stages in a different order. The various embodiments described herein and elements thereof may also be combined to provide further embodiments. In some cases, well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of embodiments of the present technology.
Where the context permits, singular or plural terms may also include the plural or singular terms, respectively. Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the terms “comprising” and the like are used throughout the disclosure to mean including at least the recited feature(s) such that any greater number of the same feature(s) and/or additional types of other features are not precluded. It will also be appreciated that various modifications may be made to the described embodiments without deviating from the present technology. Further, while advantages associated with certain embodiments of the present technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the present technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application is a continuation of and claims the benefit of U.S. patent application Ser. No. 13/458,120, filed Apr. 27, 2012, the disclosure of which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3125096 | Antiles et al. | Mar 1964 | A |
3298371 | Lee | Jan 1967 | A |
3901241 | Allen, Jr. | Aug 1975 | A |
3924628 | Droegemueller et al. | Dec 1975 | A |
4143651 | Patel | Mar 1979 | A |
4275734 | Mitchiner | Jun 1981 | A |
4483341 | Witteles | Nov 1984 | A |
4602624 | Naples et al. | Jul 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4764504 | Johnson et al. | Aug 1988 | A |
4890623 | Cook et al. | Jan 1990 | A |
4976711 | Parins et al. | Dec 1990 | A |
5108390 | Potocky et al. | Apr 1992 | A |
5190539 | Fletcher et al. | Mar 1993 | A |
5300068 | Rosar et al. | Apr 1994 | A |
5308323 | Sogawa et al. | May 1994 | A |
5334181 | Rubinsky et al. | Aug 1994 | A |
5342301 | Saab | Aug 1994 | A |
5358514 | Schulman et al. | Oct 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5383856 | Bersin | Jan 1995 | A |
5417355 | Broussalian et al. | May 1995 | A |
5423744 | Gencheff et al. | Jun 1995 | A |
5425364 | Imran | Jun 1995 | A |
5484400 | Edwards et al. | Jan 1996 | A |
5571147 | Sluijter et al. | Nov 1996 | A |
5588964 | Imran et al. | Dec 1996 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5624392 | Saab | Apr 1997 | A |
5626576 | Janssen | May 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5688266 | Edwards et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5758505 | Dobak, III et al. | Jun 1998 | A |
5772590 | Webster, Jr. | Jun 1998 | A |
5807391 | Wijkamp | Sep 1998 | A |
5837003 | Ginsburg | Nov 1998 | A |
5860970 | Goddard et al. | Jan 1999 | A |
5860974 | Abele | Jan 1999 | A |
5865787 | Shapland et al. | Feb 1999 | A |
5868735 | Lafontaine | Feb 1999 | A |
5893885 | Webster et al. | Apr 1999 | A |
5902299 | Jayaraman | May 1999 | A |
5944710 | Dev et al. | Aug 1999 | A |
5954719 | Chen et al. | Sep 1999 | A |
5971979 | Joye et al. | Oct 1999 | A |
5983141 | Sluijter et al. | Nov 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6012457 | Lesh | Jan 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6024752 | Horn et al. | Feb 2000 | A |
6032675 | Rubinsky | Mar 2000 | A |
6036687 | Laufer et al. | Mar 2000 | A |
6056744 | Edwards | May 2000 | A |
6066134 | Eggers et al. | May 2000 | A |
6091995 | Ingle et al. | Jul 2000 | A |
6099524 | Lipson et al. | Aug 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6135999 | Fanton et al. | Oct 2000 | A |
6142991 | Schatzberger | Nov 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6149620 | Baker et al. | Nov 2000 | A |
6161048 | Sluijter et al. | Dec 2000 | A |
6161049 | Rudie et al. | Dec 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6190356 | Bersin | Feb 2001 | B1 |
6219577 | Brown, III et al. | Apr 2001 | B1 |
6224592 | Eggers et al. | May 2001 | B1 |
6237355 | Li | May 2001 | B1 |
6241722 | Dobak et al. | Jun 2001 | B1 |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6273886 | Edwards et al. | Aug 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6283959 | Lalonde et al. | Sep 2001 | B1 |
6290696 | Lafontaine | Sep 2001 | B1 |
6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
6314325 | Fitz | Nov 2001 | B1 |
6322558 | Taylor et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6355029 | Joye et al. | Mar 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6428534 | Joye et al. | Aug 2002 | B1 |
6432102 | Joye et al. | Aug 2002 | B2 |
6451045 | Walker et al. | Sep 2002 | B1 |
6468297 | Williams et al. | Oct 2002 | B1 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6496737 | Rudie et al. | Dec 2002 | B2 |
6497703 | Korteling et al. | Dec 2002 | B1 |
6506189 | Rittman, III et al. | Jan 2003 | B1 |
6514226 | Levin et al. | Feb 2003 | B1 |
6514245 | Williams et al. | Feb 2003 | B1 |
6517533 | Swaminathan | Feb 2003 | B1 |
6522926 | Kieval et al. | Feb 2003 | B1 |
6527739 | Bigus et al. | Mar 2003 | B1 |
6527765 | Kelman et al. | Mar 2003 | B2 |
6537271 | Murray et al. | Mar 2003 | B1 |
6540734 | Chiu et al. | Apr 2003 | B1 |
6542781 | Koblish et al. | Apr 2003 | B1 |
6551309 | LePivert | Apr 2003 | B1 |
6562034 | Edwards et al. | May 2003 | B2 |
6575933 | Wittenberger et al. | Jun 2003 | B1 |
6602246 | Joye et al. | Aug 2003 | B1 |
6602247 | Lalonde | Aug 2003 | B2 |
6610083 | Keller et al. | Aug 2003 | B2 |
6616624 | Kieval | Sep 2003 | B1 |
6622731 | Daniel et al. | Sep 2003 | B2 |
6635054 | Fjield et al. | Oct 2003 | B2 |
6640120 | Swanson et al. | Oct 2003 | B1 |
6648878 | Lafontaine | Nov 2003 | B2 |
6648879 | Joye et al. | Nov 2003 | B2 |
6666858 | Lafontaine | Dec 2003 | B2 |
6673066 | Werneth | Jan 2004 | B2 |
6685648 | Flaherty et al. | Feb 2004 | B2 |
6685732 | Kramer | Feb 2004 | B2 |
6706037 | Zvuloni et al. | Mar 2004 | B2 |
6709431 | Lafontaine | Mar 2004 | B2 |
6711444 | Koblish | Mar 2004 | B2 |
6736835 | Pellegrino et al. | May 2004 | B2 |
6752805 | Maguire et al. | Jun 2004 | B2 |
6755823 | Lalonde | Jun 2004 | B2 |
6786900 | Joye et al. | Sep 2004 | B2 |
6786901 | Joye et al. | Sep 2004 | B2 |
6807444 | Tu et al. | Oct 2004 | B2 |
6811550 | Holland et al. | Nov 2004 | B2 |
6824543 | Lentz | Nov 2004 | B2 |
6845267 | Harrison et al. | Jan 2005 | B2 |
6850801 | Kieval et al. | Feb 2005 | B2 |
6869431 | Maguire et al. | Mar 2005 | B2 |
6875209 | Zvuloni et al. | Apr 2005 | B2 |
6885888 | Rezai | Apr 2005 | B2 |
6893436 | Woodard et al. | May 2005 | B2 |
6905510 | Saab | Jun 2005 | B2 |
6908462 | Joye et al. | Jun 2005 | B2 |
6923808 | Taimisto | Aug 2005 | B2 |
6929639 | Lafontaine | Aug 2005 | B2 |
6939346 | Kannenberg et al. | Sep 2005 | B2 |
6955174 | Joye et al. | Oct 2005 | B2 |
6972015 | Joye et al. | Dec 2005 | B2 |
6981382 | Lentz et al. | Jan 2006 | B2 |
6989009 | Lafontaine | Jan 2006 | B2 |
7001378 | Yon et al. | Feb 2006 | B2 |
7022120 | Lafontaine | Apr 2006 | B2 |
7060062 | Joye et al. | Jun 2006 | B2 |
7081112 | Joye et al. | Jul 2006 | B2 |
7081115 | Taimisto | Jul 2006 | B2 |
7101368 | Lafontaine | Sep 2006 | B2 |
7149574 | Yun et al. | Dec 2006 | B2 |
7156840 | Lentz et al. | Jan 2007 | B2 |
7162303 | Levin et al. | Jan 2007 | B2 |
7172589 | Lafontaine | Feb 2007 | B2 |
7189227 | Lafontaine | Mar 2007 | B2 |
7221979 | Zhou et al. | May 2007 | B2 |
7288089 | Yon et al. | Oct 2007 | B2 |
7300433 | Lane et al. | Nov 2007 | B2 |
7306590 | Swanson | Dec 2007 | B2 |
7357797 | Ryba | Apr 2008 | B2 |
7381200 | Katoh et al. | Jun 2008 | B2 |
7387126 | Cox et al. | Jun 2008 | B2 |
7390894 | Weinshilboum et al. | Jun 2008 | B2 |
7449018 | Kramer | Nov 2008 | B2 |
7487780 | Hooven | Feb 2009 | B2 |
7507233 | Littrup et al. | Mar 2009 | B2 |
7556624 | Laufer et al. | Jul 2009 | B2 |
7604631 | Reynolds | Oct 2009 | B2 |
7617005 | Demarais et al. | Nov 2009 | B2 |
7620451 | Demarais et al. | Nov 2009 | B2 |
7641679 | Joye et al. | Jan 2010 | B2 |
7647115 | Levin et al. | Jan 2010 | B2 |
7653438 | Deem et al. | Jan 2010 | B2 |
7717948 | Demarais et al. | May 2010 | B2 |
7727191 | Mihalik et al. | Jun 2010 | B2 |
7758571 | Saadat | Jul 2010 | B2 |
7778703 | Gross et al. | Aug 2010 | B2 |
7785289 | Rios et al. | Aug 2010 | B2 |
7861725 | Swanson | Jan 2011 | B2 |
7892201 | Laguna | Feb 2011 | B1 |
7947014 | Kien | May 2011 | B2 |
7972327 | Eberl et al. | Jul 2011 | B2 |
8012147 | Lafontaine | Sep 2011 | B2 |
8062289 | Babaev | Nov 2011 | B2 |
8080006 | Lafontaine et al. | Dec 2011 | B2 |
8088125 | Lafontaine | Jan 2012 | B2 |
8123741 | Marrouche et al. | Feb 2012 | B2 |
8128617 | Bencini et al. | Mar 2012 | B2 |
8131371 | Demarais et al. | Mar 2012 | B2 |
8131372 | Levin et al. | Mar 2012 | B2 |
8140170 | Rezai et al. | Mar 2012 | B2 |
8145317 | Demarais et al. | Mar 2012 | B2 |
8150518 | Levin et al. | Apr 2012 | B2 |
8150519 | Demarais et al. | Apr 2012 | B2 |
8150520 | Demarais et al. | Apr 2012 | B2 |
8175711 | Demarais et al. | May 2012 | B2 |
8187261 | Watson | May 2012 | B2 |
8439909 | Wang et al. | May 2013 | B2 |
8469919 | Ingle et al. | Jun 2013 | B2 |
8473067 | Hastings et al. | Jun 2013 | B2 |
8475441 | Babkin et al. | Jul 2013 | B2 |
8480663 | Ingle et al. | Jul 2013 | B2 |
8480664 | Watson et al. | Jul 2013 | B2 |
8663211 | Fourkas et al. | Mar 2014 | B2 |
8740895 | Mayse et al. | Jun 2014 | B2 |
8777943 | Mayse | Jul 2014 | B2 |
8814899 | Pepper | Aug 2014 | B2 |
9101343 | Duong et al. | Aug 2015 | B2 |
9259559 | Pepper | Feb 2016 | B2 |
20020045893 | Lane et al. | Apr 2002 | A1 |
20020045894 | Joye | Apr 2002 | A1 |
20020065487 | Wollschlager | May 2002 | A1 |
20020087208 | Koblish et al. | Jul 2002 | A1 |
20020107515 | Edwards et al. | Aug 2002 | A1 |
20020120258 | Lalonde | Aug 2002 | A1 |
20020139379 | Edwards et al. | Oct 2002 | A1 |
20020165532 | Hill et al. | Nov 2002 | A1 |
20020183682 | Darvish et al. | Dec 2002 | A1 |
20030014095 | Kramer et al. | Jan 2003 | A1 |
20030036752 | Joye et al. | Feb 2003 | A1 |
20030050635 | Truckai et al. | Mar 2003 | A1 |
20030050681 | Pianca et al. | Mar 2003 | A1 |
20030060762 | Zvuloni | Mar 2003 | A1 |
20030060858 | Kieval et al. | Mar 2003 | A1 |
20030074039 | Puskas | Apr 2003 | A1 |
20030088189 | Tu et al. | May 2003 | A1 |
20030088240 | Saadat | May 2003 | A1 |
20030109912 | Joye | Jun 2003 | A1 |
20030125721 | Yon | Jul 2003 | A1 |
20030125790 | Fastovsky et al. | Jul 2003 | A1 |
20030181897 | Thomas et al. | Sep 2003 | A1 |
20030195507 | Stewart et al. | Oct 2003 | A1 |
20030199861 | Lafontaine | Oct 2003 | A1 |
20030199863 | Swanson et al. | Oct 2003 | A1 |
20030216792 | Levin et al. | Nov 2003 | A1 |
20030229340 | Sherry et al. | Dec 2003 | A1 |
20030233099 | Danek et al. | Dec 2003 | A1 |
20040010289 | Biggs et al. | Jan 2004 | A1 |
20040024392 | Lewis et al. | Feb 2004 | A1 |
20040167509 | Taimisto | Aug 2004 | A1 |
20040215186 | Cornelius et al. | Oct 2004 | A1 |
20040243119 | Lane et al. | Dec 2004 | A1 |
20040267250 | Yon et al. | Dec 2004 | A1 |
20050080409 | Young et al. | Apr 2005 | A1 |
20050096647 | Steinke et al. | May 2005 | A1 |
20050187579 | Danek et al. | Aug 2005 | A1 |
20050209587 | Joye et al. | Sep 2005 | A1 |
20050228367 | Abboud | Oct 2005 | A1 |
20050228460 | Levin et al. | Oct 2005 | A1 |
20050240117 | Zvuloni et al. | Oct 2005 | A1 |
20060084962 | Joye | Apr 2006 | A1 |
20060085054 | Zikorus et al. | Apr 2006 | A1 |
20060095029 | Young et al. | May 2006 | A1 |
20060100618 | Chan et al. | May 2006 | A1 |
20060161102 | Newcomb | Jul 2006 | A1 |
20060167438 | Kalser | Jul 2006 | A1 |
20060206150 | Demarais et al. | Sep 2006 | A1 |
20060212027 | Marrouche et al. | Sep 2006 | A1 |
20060212076 | Demarais et al. | Sep 2006 | A1 |
20060247611 | Abboud et al. | Nov 2006 | A1 |
20060264823 | Newcomb | Nov 2006 | A1 |
20060270982 | Mihalik | Nov 2006 | A1 |
20060271111 | Demarais et al. | Nov 2006 | A1 |
20070049924 | Rahn | Mar 2007 | A1 |
20070093710 | Maschke | Apr 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070185445 | Nahon et al. | Aug 2007 | A1 |
20070265687 | Deem et al. | Nov 2007 | A1 |
20070299433 | Williams et al. | Dec 2007 | A1 |
20080097251 | Babaev | Apr 2008 | A1 |
20080171974 | Lafontaine et al. | Jul 2008 | A1 |
20080208182 | Lafontaine et al. | Aug 2008 | A1 |
20080300584 | Lentz et al. | Dec 2008 | A1 |
20080306475 | Lentz et al. | Dec 2008 | A1 |
20080312644 | Fourkas et al. | Dec 2008 | A1 |
20080319513 | Pu et al. | Dec 2008 | A1 |
20090036948 | Levin et al. | Feb 2009 | A1 |
20090171333 | Hon | Jul 2009 | A1 |
20090182316 | Bencini | Jul 2009 | A1 |
20090182317 | Bencini | Jul 2009 | A1 |
20090209949 | Ingle et al. | Aug 2009 | A1 |
20090221955 | Babaev | Sep 2009 | A1 |
20090281533 | Ingle et al. | Nov 2009 | A1 |
20090287202 | Ingle et al. | Nov 2009 | A1 |
20090299355 | Bencini et al. | Dec 2009 | A1 |
20100049184 | George et al. | Feb 2010 | A1 |
20100069900 | Shirley | Mar 2010 | A1 |
20100100087 | Mazzone et al. | Apr 2010 | A1 |
20100106148 | Joye et al. | Apr 2010 | A1 |
20100114269 | Wittenberger et al. | May 2010 | A1 |
20100125266 | Deem et al. | May 2010 | A1 |
20100130970 | Williams et al. | May 2010 | A1 |
20100137860 | Demarais et al. | Jun 2010 | A1 |
20100137952 | Demarais et al. | Jun 2010 | A1 |
20100179526 | Lawrence | Jul 2010 | A1 |
20100179527 | Watson et al. | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100198203 | Kuck et al. | Aug 2010 | A1 |
20100217189 | Pepper | Aug 2010 | A1 |
20100222786 | Kassab | Sep 2010 | A1 |
20100222851 | Deem et al. | Sep 2010 | A1 |
20100222854 | Demarais et al. | Sep 2010 | A1 |
20100234838 | Watson | Sep 2010 | A1 |
20100249766 | Saadat | Sep 2010 | A1 |
20100256621 | Babkin et al. | Oct 2010 | A1 |
20100274189 | Kurth | Oct 2010 | A1 |
20100280507 | Babkin et al. | Nov 2010 | A1 |
20100292640 | Kien | Nov 2010 | A1 |
20110125143 | Gross et al. | May 2011 | A1 |
20110152855 | Mayse et al. | Jun 2011 | A1 |
20110257642 | Griggs, III | Oct 2011 | A1 |
20110263921 | Vrba et al. | Oct 2011 | A1 |
20110270238 | Rizq et al. | Nov 2011 | A1 |
20110282272 | Lafontaine | Nov 2011 | A1 |
20120029509 | Smith | Feb 2012 | A1 |
20120029511 | Smith et al. | Feb 2012 | A1 |
20120089047 | Ryba et al. | Apr 2012 | A1 |
20120109021 | Hastings et al. | May 2012 | A1 |
20120123261 | Jenson et al. | May 2012 | A1 |
20120130289 | Demarais et al. | May 2012 | A1 |
20120130345 | Levin et al. | May 2012 | A1 |
20120130360 | Buckley et al. | May 2012 | A1 |
20120130368 | Jenson | May 2012 | A1 |
20120136417 | Buckley et al. | May 2012 | A1 |
20120136418 | Buckley et al. | May 2012 | A1 |
20120143097 | Pike, Jr. | Jun 2012 | A1 |
20120143177 | Avitall | Jun 2012 | A1 |
20120150267 | Buckley et al. | Jun 2012 | A1 |
20120172837 | Demarais et al. | Jul 2012 | A1 |
20120253336 | Littrup et al. | Oct 2012 | A1 |
20130090650 | Jenson et al. | Apr 2013 | A1 |
20130123770 | Smith | May 2013 | A1 |
20130184696 | Fourkas et al. | Jul 2013 | A1 |
20130345688 | Babkin et al. | Dec 2013 | A1 |
20140046313 | Pederson et al. | Feb 2014 | A1 |
20140066914 | Lafontaine | Mar 2014 | A1 |
20140276724 | Goshayeshgar | Sep 2014 | A1 |
20140276728 | Goshayeshgar | Sep 2014 | A1 |
20140276811 | Koblish et al. | Sep 2014 | A1 |
20140364893 | Pepper | Dec 2014 | A1 |
20150105764 | Rizq et al. | Apr 2015 | A1 |
20150231378 | Pepper | Aug 2015 | A1 |
Number | Date | Country |
---|---|---|
1408451 | Apr 2003 | CN |
4406451 | Sep 1995 | DE |
102005041601 | Apr 2007 | DE |
0655225 | May 1995 | EP |
0955012 | Nov 1999 | EP |
1129670 | Sep 2001 | EP |
1164963 | Jan 2002 | EP |
1210959 | Jun 2002 | EP |
1389477 | Feb 2004 | EP |
1502553 | Feb 2005 | EP |
1559362 | Aug 2005 | EP |
2558016 | Feb 2013 | EP |
2598070 | Jun 2013 | EP |
2598071 | Jun 2013 | EP |
2608837 | Jul 2013 | EP |
1422535 | Jan 1976 | GB |
2283678 | May 1995 | GB |
2289414 | Nov 1995 | GB |
718099 | Feb 1980 | SU |
1153901 | May 1985 | SU |
1329781 | Aug 1987 | SU |
1378835 | Mar 1988 | SU |
1771725 | Oct 1992 | SU |
WO-199407446 | Apr 1994 | WO |
WO-1995025472 | Sep 1995 | WO |
WO-9531142 | Nov 1995 | WO |
WO-9725011 | Jul 1997 | WO |
WO-1997036548 | Oct 1997 | WO |
WO1998042403 | Oct 1998 | WO |
WO-9900060 | Jan 1999 | WO |
WO-9905979 | Feb 1999 | WO |
WO-9927862 | Jun 1999 | WO |
WO-0047118 | Aug 2000 | WO |
WO-2001022897 | Apr 2001 | WO |
WO-0164145 | Sep 2001 | WO |
WO-2001070114 | Sep 2001 | WO |
WO-0200128 | Jan 2002 | WO |
WO-0204042 | Jan 2002 | WO |
WO-0207625 | Jan 2002 | WO |
WO-0207628 | Jan 2002 | WO |
WO-0213710 | Feb 2002 | WO |
WO-0215807 | Feb 2002 | WO |
WO-02058576 | Aug 2002 | WO |
WO-03020334 | Mar 2003 | WO |
WO-2003022167 | Mar 2003 | WO |
WO-03061496 | Jul 2003 | WO |
WO-2003082080 | Oct 2003 | WO |
WO-2005030072 | Apr 2005 | WO |
WO-2005038357 | Apr 2005 | WO |
WO--2005041748 | May 2005 | WO |
WO-2005110528 | Nov 2005 | WO |
WO-2006041881 | Apr 2006 | WO |
WO-2006096272 | Sep 2006 | WO |
WO-2006105121 | Oct 2006 | WO |
WO-2006124177 | Nov 2006 | WO |
WO-2007008954 | Jan 2007 | WO |
WO-2007078997 | Jul 2007 | WO |
WO-2008049084 | Apr 2008 | WO |
WO-2008131037 | Oct 2008 | WO |
WO-2011056684 | May 2011 | WO |
WO-2011082278 | Jul 2011 | WO |
WO-2011082279 | Jul 2011 | WO |
WO-2012016135 | Feb 2012 | WO |
WO-2012016137 | Feb 2012 | WO |
WO-2012058430 | May 2012 | WO |
WO-2013074683 | May 2013 | WO |
WO-2013106859 | Jul 2013 | WO |
WO-2013163325 | Oct 2013 | WO |
WO-2014150204 | Sep 2014 | WO |
WO-2014158727 | Oct 2014 | WO |
WO-2014164445 | Oct 2014 | WO |
Entry |
---|
U.S. Appl. No. 95/002,110, filed Aug. 29, 2012, Demarais et al. |
U.S. Appl. No. 95/002,209, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,233, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,243, filed Sep. 13, 2012, Levin et al. |
U.S. Appl. No. 95/002,253, filed Sep. 13, 2012, Demarais et al. |
U.S. Appl. No. 95/002,255, filed Sep. 13, 2012, Demarais et al. |
U.S. Appl. No. 95/002,292, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,327, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,335, filed Sep. 14, 2012, Demarais et al. |
U.S. Appl. No. 95/002,336, filed Sep. 14, 2012, Levin et al. |
U.S. Appl. No. 95/002,356, filed Sep. 14, 2012, Demarais et al. |
“2011 Edison Award Winners.” Edison Awards: Honoring Innovations & Innovators, 2011, 6 pages, <http://www.edisonawards.com/BestNewProduct—2011.php>. |
“2012 top 10 advances in heart disease and stroke research: American Heart Association/America Stroke Association Top 10 Research Report.” American Heart Association, Dec. 17, 2012, 5 pages, <http://newsroom.heart.org/news/2012-top-10-advances-in-heart-241901>. |
“Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension.” PR Newswire, Jun. 3, 2010, 2 pages, <http://www.prnewswire.com/news-releases/ardianr-receives-2010-europer-innovation-award-and-demonstrates-further-durability-of-renal-denervation-treatment-for-hypertension-95545014.html>. |
“Boston Scientific to Acquire Vessix Vascular, Inc.: Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology.” Boston Scientific: Advancing science for life—Investor Relations, Nov. 8, 2012, 2 pages, <http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-newsArticle&id=1756108>. |
“Cleveland Clinic Unveils Top 10 Medical Innovations for 2012: Experts Predict Ten Emerging Technologies that will Shape Health Care Next Year.” Cleveland Clinic, Oct. 6, 2011, 2 pages. <http://my.clevelandclinic.org/media—relations/library/2011/2011-10-6-cleveland-clinic-unveils-top-10-medical-innovations-for-2012.aspx>. |
“Does renal denervation represent a new treatment option for resistant hypertension?” Interventional News, Aug. 3, 2010, 2 pages. <http://www.cxvascular.com/in-latest-news/interventional-news---latest-news/does-renal-denervation-represent-a-new-treatment-option-for-resistant-hypertension>. |
“Iberis—Renal Sympathetic Denervation System: Turning innovation into quality care.” [Brochure], Terumo Europe N.V., 2013, Europe, 3 pages. |
“Neurotech Reports Announces Winners of Gold Electrode Awards.” Neurotech business report, 2009. 1 page. <http://www.neurotechreports.com/pages/goldelectrodes09.html>. |
“Quick. Consistent. Controlled. OneShot renal Denervation System” [Brochure], Covidien: positive results for life, 2013, (n.l.), 4 pages. |
“Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million.” Vessix Vascular Pharmaceutical Intelligence: A blog specializing in Pharmaceutical Intelligence and Analytics, Nov. 8, 2012, 21 pages, <http://pharmaceuticalintelligence.com/tag/vessix-vascular/>. |
“The Edison Awards™” Edison Awards: Honoring Innovations & Innovators, 2013, 2 pages, <http://www.edisonawards.com/Awards.php>. |
“The Future of Renal denervation for the Treatment of Resistant Hypertension.” St. Jude Medical, Inc., 2012, 12 pages. |
“Vessix Renal Denervation System: So Advanced It's Simple.” [Brochure], Boston Scientific: Advancing science for life, 2013, 6 pages. |
Asbell, Penny, “Conductive Keratoplasty For The Correction of Hyperopia.” Tr Am Ophth Soc, 2001, vol. 99, 10 pages. |
Badoer, Emilio, “Cardiac afferents play the dominant role in renal nerve inhibition elicited by volume expansion in the rabbit.” Am J Physiol Regul Integr Comp Physiol, vol. 274, 1998, 7 pages. |
Bengel, Frank, “Serial Assessment of Sympathetic Reinnervation After Orthotopic Heart Transplantation: A longitudinal Study Using PET and C-11 Hydroxyephedrine.” Circulation, vol. 99, 1999,7 pages. |
Benito, F., et al. “Radiofrequency catheter ablation of accessory pathways in infants.” Heart, 78:160-162 (1997). |
Bettmann, Michael, Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association, Circulation, vol. 97, 1998, 4 pages. |
Bohm, Michael et al., “Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry.” EuroIntervention, vol. 9, 2013, 9 pages. |
Brosky, John, “EuroPCR 2013: CE-approved devices line up for renal denervation approval.” Medical Device Daily, May 28, 2013, 3 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines—article&forceid=83002>. |
Davis, Mark et al., “Effectiveness of Renal Denervation Therapy for Resistant Hypertension.” Journal of the American College of Cardiology, vol. 62, No. 3, 2013, 11 pages. |
Dibona, G.F. “Sympathetic nervous system and kidney in hypertension.” Nephrol and Hypertension, 11: 197-200 (2002). |
Dubuc, M., et al., “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter.” J Intery Cardiac Electrophysiol, 2:285-292 (1998). |
Final Office Action, U.S. Appl. No. 12/827,700, dated Feb. 5, 2013, 61 pages. |
Geisler, Benjamin et al., “Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension.” Journal of the American College of Cardiology, col. 60, No. 14, 2012, 7 pages. |
Gelfand, M., et al., “Treatment of renal failure and hypertension.” U.S. Appl. No. 60/442,970, filed Jan. 29, 2003, 23 pages. |
Gertner, Jon, “Meet the Tech Duo That's Revitalizing The Medical Device Industry.” Fast Company, Apr. 15, 2013, 6:00 AM, 17 pages, <http://www.fastcompany.com/3007845/meet-tech-duo-thats-revitalizing-medical-device-industry>. |
Golwyn, D. H., Jr., et al. “Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease.” JVIR, 8: 527-533 (1997). |
Hall, W. H., et al. “Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor.” Am. J. Roentgenol,174: 1592-1594 (2000). |
Han, Y.-M, et al., “Renal artery ebolization with diluted hot contrast medium: An experimental study.” J Vasc Interv Radiol, 12: 862-868 (2001). |
Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin. Sci, 87: 13-19 (1994). |
Hendee, W. R. et al. “Use of Animals in Biomedical Research: The Challenge and Response.” American Medical Association White Paper (1988) 39 pages. |
Hering, Dagmara et al., “Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.” EuroIntervention, vol. 9, 2013, 9 pages. |
Huang et al., “Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats.” Hypertension 32 (1998) pp. 249-254. |
Imimdtanz, “Medtronic awarded industry's highest honor for renal denervation system.” The official blog of Medtronic Australasia, Nov. 12, 2012, 2 pages, <http://97waterlooroad.wordpress.com/2012/11/12/medtronic-awarded-industrys-highest-honour-for-renal-denervation-system/>. |
Kaiser, Chris, AHA Lists Year's Big Advances in CV Research, medpage Today, Dec. 18, 2012, 4 pages, <http://www.medpagetoday.com/Cardiology/PCI/36509>. |
Kompanowska, E., et al., “Early Effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow.” J Physiol, 531. 2:527-534 (2001). |
Lee, S.J., et al. “Ultrasonic energy in endoscopic surgery.” Yonsei Med J, 40:545-549 (1999). |
Linz, Dominik et al., “Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs.” Heart Rhythm, vol. 0, No. 0, 2013, 6 pages. |
Lustgarten, D.L.,et al., “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias.” Progr Cardiovasc Dis, 41:481-498 (1999). |
Mabin, Tom et al., “First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.” EuroIntervention, vol. 8, 2012, 5 pages. |
Mahfoud, Felix et al., “Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Circulation, 2013, 25 pages. |
Mahfoud, Felix et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.” European Heart Journal, 2013, 9 pages. |
Mahfoud, Felix et al., “Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension.” Hypertension, 2012, 6 pages. |
Medical-Dictionary.com, Definition of “Animal Model,” http://medical-dictionary.com (search “Animal Model”), 2005, 1 page. |
Medtronic, Inc., Annual Report (Form 10-K) (Jun. 28, 2011) 44 pages. |
Millard, F. C., et al, “Renal Embolization for ablation of function in renal failure and hypertension.” Postgraduate Medical Journal, 65, 729-734, (1989). |
Oliveira, V., et al., “Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats.” Hypertension, 19:II-17-II-21 (1992). |
Ong, K. L., et al. “Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004.” Hypertension, 49: 69-75 (2007) (originally published online Dec. 11, 2006). |
Ormiston, John et al., “First-in-human use of the OneShot™ renal denervation system from Covidien.” EuroIntervention, vol. 8, 2013, 4 pages. |
Ormiston, John et al., “Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial.” EuroIntervention, vol. 9, 2013, 5 pages. |
Pedersen, Amanda, “TCT 2012: Renal denervation device makers play show and tell.” Medical Device Daily, Oct. 26, 2012, 2 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines—article&forceid=80880>. |
Peet, M., “Hypertension and its Surgical Treatment by bilateral supradiaphragmatic splanchnicectomy” Am J Surgery (1948) pp. 48-68. |
Renal Denervation (RDN), Symplicity RDN System Common Q&A (2011), 4 pages, http://www.medtronic.com/rdn/mediakit/RDN%20FAQ.pdf. |
Schauerte, P., et al. “Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation.” Circulation, 102:2774-2780 (2000). |
Schlaich, Markus et al., “Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects.” Curr Hypertens Rep, vol. 14, 2012, 7 pages. |
Schmid, Axel et al., “Does Renal Artery Supply Indicate Treatment Success of Renal Denervation.” Cardiovasc Intervent Radiol, vol. 36, 2013, 5 pages. |
Schmieder, Roland E. et al., “Updated ESH position paper on interventional therapy of resistant hypertension.” EuroIntervention, vol. 9, 2013, 9 pages. |
Sievert, Horst, “Novelty Award EuroPCR 2010.” Euro PCR, 2010, 15 pages. |
Solis-Herruzo et al., “Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome,” J. Hepatol. 5 (1987), pp. 167-173. |
Stella, A., et al., “Effects of reversible renal denervation on haemodynamic and excretory functions on the ipsilateral and contralateral kidney in the cat.” Hypertension, 4:181-188 (1986). |
Stouffer, G. A. et al., “Catheter-based renal denervation in the treatment of resistant hypertension.” Journal of Molecular and Cellular Cardiology, vol. 62, 2013, 6 pages. |
Swartz, J.F., et al., “Radiofrequency endocardial catheter ablation of accessory atrioventricular pathway atrial insertion sites.” Circulation, 87: 487-499 (1993). |
Uchida, F., et al., “Effect of radiofrequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites.” PACE, 21:2517-2521 (1998). |
Verloop, W. L. et al., “Renal denervation: a new treatment option in resistant arterial hypertension.” Neth Heart J., Nov. 30, 2012, 6 pages, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547427/>. |
Weinstock, M., et al., “Renal denervation prevents sodium retention and hypertension in salt sensitive rabbits with genetic baroreflex impairment.” Clinical Science, 90:287-293 (1996). |
Wilcox, Josiah N., Scientific Basis Behind Renal Denervation for the Control of Hypertension, ICI 2012, Dec. 5-6, 2012. 38 pages. |
Worthley, Stephen et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.” European Heart Journal, vol. 34, 2013, 9 pages. |
Worthley, Stephen, “The St. Jude Renal Denervation System Technology and Clinical Review.” The University of Adelaide Australia, 2012, 24 pages. |
Zuern, Christine S., “Impaired Cardiac Baroflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Journal of the American College of Cardiology, 2013, doi: 10.1016/j.jacc.2013.07.046, 24 pages. |
Miller, Reed, “Finding A Future for Renal Denervation With Better Controlled Trials.” Pharma & Medtech Business Intelligence, Article # 01141006003, Oct. 6, 2014, 4 pages. |
Papademetriou, Vasilios, “Renal Denervation and Symplicity HTN-3: “Dubium Sapientiae Initium” (Doubt Is the Beginning of Wisdom)”, Circulation Research, 2014; 115: 211-214. |
Papademetriou, Vasilios et al., “Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions.” Circulation. 2014; 129: 1440-1450. |
Papademetriou, Vasilios et al., “Catheter-Based Renal Denervation for Resistant Hypertension: 12-Month Results of the EnligHTN I First-in-Human Study Using a Multielectrode Ablation System.” Hypertension. 2014; 64: 565-572. |
Doumas, Michael et al., “Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled.” The Journal of Clinical Hypertension. 2014; vol. 16, No. 6, 2 pages. |
Messerli, Franz H. et al. “Renal Denervation for Resistant Hypertension: Dead or Alive?” Healio: Cardiology today's Intervention, May/Jun. 2014, 2 pages. |
Allen, E.V., Sympathectomy for essential hypertension, Circulation, 1952, 6:131-140. |
Bello-Reuss, E. et al., “Effects of Acute Unilateral Renal Denervation in the Rat,” Journal of Clinical Investigation, vol. 56, Jul. 1975, pp. 208-217. |
Bello-Reuss, E. et al., “Effects of Renal Sympathetic Nerve Stimulation on Proximal Water and Sodium Reabsorption,” Journal of Clinical Investigation, vol. 57, Apr. 1976, pp. 1104-1107. |
Bhandari, A. and Ellias, M., “Loin Pain Hematuria Syndrome: Pain Control with RFA to the Splanchanic Plexus,” The Pain Clinc, 2000, vol. 12, No. 4, pp. 323-327. |
Curtis, John J. et al., “Surgical Therapy for Persistent Hypertension After Renal Transplantation” Transplantation, 31:125-128 (1981). |
Dibona, Gerald F. et al., “Neural Control of Renal Function,” Physiological Reviews, vol. 77, No. 1, Jan. 1997, The American Physiological Society 1997, pp. 75-197. |
Dibona, Gerald F., “Neural Control of the Kidney—Past, Present and Future,” Nov. 4, 2002, Novartis Lecture, Hypertension 2003, 41 part 2, 2002 American Heart Association, Inc., pp. 621-624. |
Janssen, Ben J.A. et al., “Effects of Complete Renal Denervation and Selective Afferent Renal Denervation on the Hypertension Induced by Intrarenal Norepinephrine Infusion in Conscious Rats”, Journal of Hypertension 1989, 7: 447-455. |
Katholi, Richard E., “Renal Nerves in the Pathogenesis of Hypertension in Experimental Animals and Humans,” Am J. Physiol. vol. 245, 1983, the American Physiological Society 1983, pp. F1-F14. |
Krum, Henry et al., “Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Mulitcentre Safety and Proof-of Principle Cohort Study,” Lancet 2009; 373:1275-81. |
Krum, et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension.” New England Journal of Med, Aug. 2009, 361; 9, 3 pages. |
Luippold, Gerd et al., “Chronic Renal Denervation Prevents Glomerular Hyperfiltration in Diabetic Rats”, Nephrol Dial Transplant, vol. 19, No. 2, 2004, pp. 342-347. |
Mahfoud et al. “Treatment strategies for resistant arterial hypertension” Dtsch Arztebl Int. 2011;108:725-731. |
Osborn, et al., “Effect of Renal Nerve Stimulation on Renal Blood Flow Autoregulation and Antinatriuresis During Reductions in Renal Perfusion Pressure,” Proceedings of the Society for Experimental Biology and Medicine, vol. 168, 77-81, 1981. |
Page, I.H. et al., “The Effect of Renal Denervation on Patients Suffering From Nephritis,” Feb. 27, 1935;443-458. |
Page, I.H. et al., “The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension,” J. Clin Invest. 1934;14:27-30. |
Rocha-Singh, “Catheter-Based Sympathetic Renal Denervation,” Endovascular Today, Aug. 2009, 4 pages. |
Schlaich, M.P. et al., “Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept,” Hypertension, 2009; 54:1195-1201. |
Schlaich, M.P. et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension,” N Engl J Med 2009; 361(9): 932-934. |
Smithwick, R.H. et al., “Splanchnicectomy for Essential Hypertension,” Journal Am Med Assn, 1953; 152:1501-1504. |
Symplicity HTN-1 Investigators; Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-917. |
Symplicity HTN-2 Investigators, “Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial”; Lancet, Dec. 4, 2010, vol. 376, pp. 1903-1909. |
United States Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003, 593 pages. |
Valente, John F. et al., “Laparoscopic Renal Denervation for Intractable ADPKD-Related Pain”, Nephrol Dial Transplant (2001) 16: 1 page. |
Wagner, C.D. et al., “Very Low Frequency Oscillations in Arterial Blood Pressure After Autonomic Blockade in Conscious Dogs,” Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, 1997 the American Physiological Society, pp. 2034-2039. |
International Search Report and Written Opinion of International Application No. PCT/US2013/038036, dated Jan. 15, 2014, 24 pages. |
European Search Report for European Application No. 13159256, dated Oct. 17, 2013, 6 pages. |
510K Summary of CryoGen Cryosurgery System, filed with FDA Jul. 3, 1997—approved Oct. 1, 1997, 1997, 5 pages. |
CO2/Gas Composite Regulator, Sep. 6, 2011, 2 pages. <http://www.genuineinnovations.com/composite-regulator.html>. |
CryoGen SS&E: HerOption Uterine Cryoblatin Therapy System, filed with FDA Aug. 15, 2000 approved Apr. 20, 2001, 1999, 84 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2012/063411 dated Jun. 13, 2013, 13 pages. |
Lura Harrison, Ph.D. et al., “Cryosurgical Ablation of the A-V Node-His Bundle—A New Method for Producing A-V Block,” Circulation, vol. 55, 1977 pp. 463-470. |
Medical Grade Gas Dispenser, Sep. 6, 2011, 1 page, <http://www.abd-inc.com/Frame-904990-page1namepage904990.html?refresh=1205442262133>. |
Sesia G. et al., “The use of nitrous oxide as a freezing agent in cryosurgery of the prostate,” International Surgery [Int Surg], vol. 53, 1970, pp. 82-90. |
Special Order Only Thermal Dilution Injector, Obsolete Product, Sep. 6, 2011, 1 page, <http://www.abd-inc.com/Frame-904990-page1namepage904990.html?refresh=1205442262133>. |
Torre, Douglas, MD, “Alternate Cryogens for Cryosurgery,” J. Derm. Surgery, Jun. 1975, pp. 56-58. |
Votyna SV, “Cryocatheter-tourniquet,” Meditsinskaia Tekhnika [Med Tekh], vol. 6, 1976, pp. 47-48. |
Ahmed, Humera et al., Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension, JACC Cardiovascular Interventions, vol. 5, No. 7, 2012, pp. 758-765. |
Avitall et al., “The creation of linear contiguous lesions in the atria with an expandable loop catheter,” Journal of the American College of Cardiology, 1999; 33; pp. 972-984. |
Beale et al., “Minimally Invasive Treatment for Varicose Veins: A Review of Endovenous Laser Treatment and Radiofrequency Ablation”. Lower Extremity Wounds 3(4), 2004, 10 pages. |
Blessing, Erwin et al., Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements, JACC Cardiovascular Interventions, vol. 6, No. 3, 2013, 1 page. |
ClinicalTrials.gov, Renal Denervation in Patients with uncontrolled Hypertension in Chinese (2011), 6pages. www.clinicaltrials.gov/ct2/show/NCT01390831. |
Excerpt of Operator's Manual of Boston Scientific's EPT-1000 XP Cardiac Ablation Controller & Accessories, Version of Apr. 2003, (6 pages). |
Excerpt of Operator's Manual of Boston Scientific's Maestro 30000 Cardiac Ablation System, Version of Oct. 17, 2005 , (4 pages). |
Holmes et al., Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation: Clinical Spectrum and Interventional Considerations, JACC: Cardiovascular Interventions, 2: 4, 2009, 10 pages. |
Kandarpa, Krishna et al., “Handbook of Interventional Radiologic Procedures”, Third Edition, pp. 194-210 (2002). |
Mount Sinai School of Medicine clinical trial for Impact of Renal Sympathetic Denervation of Chronic Hypertension, Mar. 2013, 11 pages. http://clinicaltrials.gov/ct2/show/NCT01628198. |
Opposition to European Patent No. EP1802370, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 20 pages. |
Opposition to European Patent No. EP2037840, Granted Dec. 7, 2011, Date of Opposition Sep. 7, 2012, 25 pages. |
Opposition to European Patent No. EP2092957, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 26 pages. |
Oz, Mehmet, Pressure Relief, TIME, Jan. 9, 2012, 2 pages. <www.time.com/time/printout/0,8816,2103278,00.html>. |
Papademetriou, Vasilios, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, Int. Journal of Hypertension, 2011, 8 pages. |
Pieper et al., “Design and Implementation of a New Computerized System for Intraoperative Cardiac Mapping.” Journal of Applied Physiology, 1991, vol. 71, No. 4, pp. 1529-1539. |
Prochnau, Dirk et al., Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter; Euro Intervention 2012, vol. 7, pp. 1077-1080. |
Purerfellner, Helmut et al., Incidence, Management, and Outcome in Significant Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation, Am. J. Cardiol , 93, Jun. 1, 2004, 4 pages. |
Purerfellner, Helmut et al., Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation, Curr. Opin. Cardio. 20 :484-490, 2005. |
Remo, Benjamin F. et al., “Safety and Efficacy of Renal Denervation as a Novel Treatment of Ventricular Tachycardia Storm in Patients with Cardiomyopathy.” Heart Rhythm, 2014, 11(4), 541-6. |
Schneider, Peter A., “Endovascular Skills—Guidewire and Catheter Skills for Endovascular Surgery,” Second Edition Revised and Expanded, 10 pages, (2003). |
ThermoCool Irrigated Catheter and Integrated Ablation System, Biosense Webster (2006), 6 pages. |
Tsao, Hsuan-Ming, Evaluation of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation, Cardiac Electrophysiology Review, 6, 2002, 4 pages. |
U.S. Appl. No. 60/852,787, filed Oct. 18, 2006, 112 pages. |
Wittkampf et al., “Control of radiofrequency lesion size by power regulation,” Journal of the American Heart Associate, 1989, 80: pp. 962-968. |
Zheng et al., “Comparison of the temperature profile and pathological effect at unipolar, bipolar and phased radiofrequency current configurations,” Journal of Interventional Cardiac Electrophysiology, 2001, pp. 401-410. |
Dodge, et al., “Lumen Diameter of Normal Human Coronary Arteries Influence of Age, Sex, Anatomic Variation, and Left Ventricular Hypertrophy or Dilation”, Circulation, 1992, vol. 86 (1), pp. 232-246. |
Doumas, et al., “Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled.” The Journal of Clinical Hypertension. 2014; vol. 16, No. 6, 2 pages. |
Opposition to European Patent No. 2,465,470, Granted Oct. 28, 2015, Date of Opposition Jul. 27, 2016, 34 pp. |
U.S. Appl. No. 11/363,867, filed Feb. 27, 2006, 70 pp. |
U.S. Appl. No. 60/813,589, filed Dec. 29, 2005, 62 pp. |
Ureter, https://en.wikipedia.org/wiki/Ureter, Jun. 2016, 6 pp. |
Number | Date | Country | |
---|---|---|---|
20160166305 A1 | Jun 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13458120 | Apr 2012 | US |
Child | 14967425 | US |